Balaji Amines Ltd

Meeting Details

• Date: 25 August 2026.
• Type/Mode: Group plant visit followed by physical investor meeting.
• Event: Plant Visit and Management Meet with Analysts/Investors.
• Location: Solapur, Maharashtra.
• Company participants: management team.
• Purpose: discuss publicly available information; no UPSI.
• Presentation: latest investor presentation available on company website.

Meeting Details

• Date and time: 21 August 2026, 4:00 PM IST.
• Type and mode: Group meeting, virtual.
• Event/organiser: Hosted by Phillip Capital (India) Private Limited.

Participants

• Key company participant: Company Secretary & Compliance Officer.

Purpose

• Purpose: Group meeting to discuss publicly available information.

Additional Notes

• Website post: Information available on Balaji Amines website.

Meeting Details

• Date and time: Friday, 21 August 2026, 4:00 P.M. IST.
• Meeting type and mode: Group meeting, virtual.
• Organiser: Hosted by Phillip Capital (India) Private Limited.
• Purpose: Interactions based on publicly available information.
• Company participants: Officials of Balaji Amines Ltd.

Business Overview

• Balaji Amines is transitioning from amines to a speciality chemicals platform via BSCL.
• Operates multi-location manufacturing across Maharashtra and Telangana with integrated value chain.
• BSCL is a 55% subsidiary focused on high-value speciality chemicals and import substitution.
• DME, NMM, ACN are key growth initiatives with import-substitution focus.

Key Operational Highlights

• 100,000 TPA DME plant commissioned in Q1 FY27, India's first commercial-scale DME.
• NMM project progressing; ACN expansion under execution, commissioning expected FY27.
• BSCL Phase I under execution; HCN, NaCN, EDTA plants targeted end-FY27; TEFO Phase II identified.
• Capex cycle of ₹1000 Cr+ nearing completion; FY27 volume growth guidance 10-15%.
• Standalone debt-free; expansion funded by internal accruals; net worth ₹2,152 Cr.

Financial Performance

• Q1 FY27 consolidated revenue ₹461 Cr, up 25.7% YoY.
• EBITDA ₹121 Cr; EBITDA margin 26%; EBIT ₹108 Cr; margin 23%.
• PAT ₹78 Cr; PAT margin 17%; EPS ₹23.13.
• FY26 consolidated revenue ₹1,454 Cr; EBITDA ₹294 Cr; PAT ₹169 Cr; standalone debt-free.

Capital Structure & Liquidity

• Standalone business is debt-free; expansions funded by internal accruals.
• Consolidated debt ₹133 Cr; net worth ₹2,152 Cr; total capital employed ₹2,285 Cr.
• Capex WIP across units ₹165.6 Cr; BSCL WIP ₹401.06 Cr.

Strategic Outlook & Growth Drivers

• EBITDA margin target 22-23% in FY27; cost leadership via backward integration.
• Growth drivers: DME, NMM, ACN and BSCL ramp-up; earnings acceleration ahead.
• Capex cycle near completion; 50+ country exports; import substitution focus.

Risks & Mitigation

• Macro headwinds and West Asia crisis; diversified portfolio and disciplined execution mitigate.
• Execution risk on NMM/ACN/BSCL; projects on track.

Governance & Leadership

• Executive Chairman: A. Prathap Reddy; MD: D. Ram Reddy; CFO: A. Srinivas Reddy.
• BSCL is a 55% subsidiary; mega project status by Government of Maharashtra.
• Consistent dividend payout; dividend per share ₹11 in FY26.

Financial highlights

• Consolidated Q1 FY27 revenue: ₹461 crore.
• EBITDA: ₹121 crore; margin 26%.
• PAT: ₹78 crore; margin 17%.
• Cash PAT: ₹97 crore; margin 20%.
• Diluted EPS: ₹23.13.
• Total volumes: 21,587 MT; Q1 FY26: 27,570 MT.
• Standalone debt: zero.

Operational and growth updates

• DME plant commissioned: 100,000 TPA; India's first commercial-scale DME facility.
• Expansion: NMM and ACN capacity expansions planned in FY27.
• Balaji Speciality Chemicals expansion: ₹750 crore; Mega Project Status under PSI 2019.
• Unit-I brownfield expansion for EDA-based products to be commissioned in FY27.
• Unit-II greenfield at MIDC Chincholi under execution; commissioning targeted FY27.
• Outlook: healthy demand, robust order pipeline, and ongoing capacity additions.

Overview

• Un-audited Q1 FY27 results for the quarter ended 30 June 2026.

Financial highlights

• Consolidated revenue ₹461 crore; EBITDA ₹121 crore; PAT ₹78 crore; Cash PAT ₹97 crore.
• EBITDA margin 26%; PAT margin 17%; Cash PAT margin 20%.
• Standalone debt is zero.

Operational milestones

• Commissioning of India's first commercial-scale 100,000 TPA DME plant completed.
• NMM and ACN capacity expansions planned for FY27.

Expansion programs

• Balaji Speciality Chemicals expansion ₹750 crore Mega Project under PSI 2019.
• Unit-I EDA-based downstream expansion to be commissioned in FY27.
• Unit-II greenfield MIDC Chincholi with HCN/NaCN/EDTA to be commissioned FY27.

Outlook

• Looking ahead, growth outlook remains positive; healthy order pipeline; ongoing capacity additions; disciplined execution.

Financial results approved

• Approved unaudited standalone Q1 2026 results for quarter ended 30 June 2026.
• Approved unaudited consolidated Q1 2026 results for quarter ended 30 June 2026.

Auditor reports / opinions

• Statutory auditors expressed an unmodified opinion on standalone results.

Consolidation scope

• Consolidated results include Balaji Speciality Chemicals Limited.

Regulatory / compliance notes

• Results prepared under Ind AS; Regulation 33 LODR compliance.

Financial results and auditor notes

• Un-audited standalone Q1 2026 results approved; quarter ended 30 June 2026.
• Un-audited consolidated Q1 2026 results approved; quarter ended 30 June 2026.
• Limited Review Reports on standalone and consolidated results noted; no material misstatement identified.
• Standalone results: revenue 42,273.75 Lakh; profit before tax 9,781.80 Lakh.
• Consolidated results: revenue 45,592.56 Lakh; profit before tax 10,620.36 Lakh.